BACKGROUND: We report on the efficacy and side effects of granulocyte collection, which is comparatively infrequently performed in Germany. METHODS: Data from 378 healthy donors who underwent 914 granulocyte collections between 1999 and 2007 were retrospectively analyzed. Donors received G-CSF (lenograstim) at a median dose of 5.58 (3.25-7.36) μg/kg body weight with (n = 243) or without (n = 57) 4 mg dexamethasone. Side effects were recorded by donor monitoring and interview (questionnaire). RESULTS: The median granulocyte yield in apheresis products was 8.47 × 10(10) (3.07-14.92 × 10(10)). Granulocyte yields correlated significantly with gender, baseline WBC, PMN and PLT counts, and nicotine consumption. Dexamethasone and lenograstim administration was more effective than lenograstim administration alone (p < 0.001). Side effects of granulocyte mobilization were generally mild: bone pain in 31.4%, headache in 19.6%, and fatigue in 15.7% of donors. During follow-up (4 weeks), pruritus and/or exanthema were reported in 17.6% of donors. CONCLUSIONS: Granulocyte mobilization with lenograstim with or without dexamethasone was a safe and effective regimen for granulocyte mobilization. Side effects were tolerable and milder than those seen in peripheral blood stem cell donors. Long-term monitoring of granulocyte donors is important to establish optimal standards for the procedure.
BACKGROUND: We report on the efficacy and side effects of granulocyte collection, which is comparatively infrequently performed in Germany. METHODS: Data from 378 healthy donors who underwent 914 granulocyte collections between 1999 and 2007 were retrospectively analyzed. Donors received G-CSF (lenograstim) at a median dose of 5.58 (3.25-7.36) μg/kg body weight with (n = 243) or without (n = 57) 4 mg dexamethasone. Side effects were recorded by donor monitoring and interview (questionnaire). RESULTS: The median granulocyte yield in apheresis products was 8.47 × 10(10) (3.07-14.92 × 10(10)). Granulocyte yields correlated significantly with gender, baseline WBC, PMN and PLT counts, and nicotine consumption. Dexamethasone and lenograstim administration was more effective than lenograstim administration alone (p < 0.001). Side effects of granulocyte mobilization were generally mild: bone pain in 31.4%, headache in 19.6%, and fatigue in 15.7% of donors. During follow-up (4 weeks), pruritus and/or exanthema were reported in 17.6% of donors. CONCLUSIONS: Granulocyte mobilization with lenograstim with or without dexamethasone was a safe and effective regimen for granulocyte mobilization. Side effects were tolerable and milder than those seen in peripheral blood stem cell donors. Long-term monitoring of granulocyte donors is important to establish optimal standards for the procedure.
Authors: M de Haas; J M Kerst; C E van der Schoot; J Calafat; C E Hack; J H Nuijens; D Roos; R H van Oers; A E von dem Borne Journal: Blood Date: 1994-12-01 Impact factor: 22.113
Authors: Christina Weingarten; Sarah Pliez; Eva Tschiedel; Corinna Grasemann; Carla Kreissig; Michael M Schündeln Journal: Eur J Pediatr Date: 2016-09-08 Impact factor: 3.183
Authors: Richard J Simpson; Austin B Bigley; Nadia Agha; Patrick J Hanley; Catherine M Bollard Journal: Exerc Sport Sci Rev Date: 2017-07 Impact factor: 6.230
Authors: Nikola Sprigg; Rebecca O'Connor; Lisa Woodhouse; Kailash Krishnan; Timothy J England; Louise A Connell; Marion F Walker; Philip M Bath Journal: PLoS One Date: 2016-09-09 Impact factor: 3.240